Prognostic factors in clinical stage I non-small cell lung cancer.

[1]  J. Mate,et al.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. , 1994, The New England journal of medicine.

[2]  J Bogaert,et al.  Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  O. Auerbach.  Histological Typing Of Lung Tumors , 1968 .

[4]  L. Rubinstein,et al.  Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Burdett,et al.  Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials , 1998, The Lancet.

[6]  S. Spiro.  Diagnosis and staging. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[7]  J. Régnard,et al.  Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancer. , 1994, The Annals of thoracic surgery.

[8]  M. Ranson,et al.  Chemotherapy in non-small cell lung cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  D. Harpole,et al.  Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence , 1995, Cancer.

[10]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[11]  J. Roth,et al.  Prognostic significance of computed tomography in resected N2 lung cancer. , 1992, The Annals of thoracic surgery.

[12]  I Yoshino,et al.  Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. , 1995, The Journal of thoracic and cardiovascular surgery.

[13]  M. Yamakido,et al.  Detection of p53 gene mutations in cytopathology and biopsy specimens from patients with lung cancer. , 1996, American journal of respiratory and critical care medicine.

[14]  J. Roth,et al.  A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. , 1994, Journal of the National Cancer Institute.

[15]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[16]  M. Kris,et al.  The role of multimodality therapy in locoregional non-small cell lung cancer. , 1997, Surgical oncology clinics of North America.

[17]  L. Rubinstein,et al.  Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group. , 1993, Journal of the National Cancer Institute.

[18]  D. Cox.  Regression Models and Life-Tables , 1972 .

[19]  M. Parmar,et al.  Postoperative radiotherapy in non-small-cell lung cancer , 1998, The Lancet.

[20]  Yoshihiro Matsuno,et al.  Surgically Curable “Early” Adenocarcinoma in the Periphery of the Lung , 1994, The American journal of surgical pathology.